e-learning
resources
Copenhagen 2005
Saturday 17.09.2005
PG15 - Therapeutic options for interstitial lung diseases in 2005
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapeutic options and management of pulmonary fibrosis: old and new
R. M. Du Bois (London, United Kingdom)
Source:
Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005
Session:
PG15 - Therapeutic options for interstitial lung diseases in 2005
Session type:
Postgraduate Course
Number:
73
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. M. Du Bois (London, United Kingdom). Therapeutic options and management of pulmonary fibrosis: old and new. Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 39: 359-365
Year: 2012
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Treatment of combined pulmonary fibrosis and emphysema
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
Can current guidelines improve the diagnosis of a usual interstitial pneumonia among general radiologists?
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
The diagnostic role of cryobiopsy in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions
Year: 2013
Histopathological assessment and classification
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Histology and pathogenesis of usual interstitial pneumonia (UIP)
versus
nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment
Source: Virtual Congress 2020 – When the lung gets stiff
Year: 2020
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013
Clinical categorisation of idiopathic interstitial pneumonia
Source: Annual Congress 2005 - Idiopathic pulmonary fibrosis: new concepts in its pathogenesis and management
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept